Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Art Of Cutting Costs Without Jeopardizing Growth: An Interview With Merck Serono's Belén Garijo

Executive Summary

Having emerged from a radical restructuring with new senior management, a revamped portfolio and a strategic ambition to morph into an oncology powerhouse on the back of its emerging markets business, CEO Belén Garijo says Merck Serono is poised to enter its growth phase.

You may also be interested in...



Merck KGAA Rebuilds Its R&D Portfolio, Re-Aligns Into Three Businesses

The diversified German company eschews the tightening of focus seen in other European pharmaceutical companies, but does subdivide its business into three units: health care, life sciences and performance materials.

Merck KGAA Rebuilds Its R&D Portfolio, Re-Aligns Into Three Businesses

The diversified German company eschews the tightening of focus seen in other European pharmaceutical companies, but does subdivide its business into three units: health care, life sciences and performance materials.

Merck KGaA Finds R&D Nuggets: Plans Further Atacicept Studies In Lupus

A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel